New drug combo shows promise for untreated liver cancer
NCT ID NCT04487067
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 3 trial tested a combination of two drugs, atezolizumab and bevacizumab, in 152 people with advanced liver cancer that could not be surgically removed and had not been treated before. The goal was to check safety and how well the treatment works. The study was open-label and single-arm, meaning everyone got the same treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab (Tecentriq) and bevacizumab (Avastin)
What this could lead to
If successful, this combination could become a standard first-line treatment for advanced liver cancer, helping control the disease and extend survival.
What could go wrong
This is a single-arm study without a comparison group, so results may be less definitive. Side effects like bleeding are a known risk with these drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O. S. Orsola Malpighi
Bologna, Emilia-Romagna, 40138, Italy
-
A.O. Universitaria S. Martino Di Genova
Genoa, Liguria, 16132, Italy
-
A.O.U Careggi
Florence, Tuscany, 50124, Italy
-
A.O.U. Cagliari-P.O. Monserrato
Cagliari, Sardinia, 09100, Italy
-
A.O.U. Policlinico Paolo Giaccone
Palermo, Sicily, 90127, Italy
-
Arcispedale Santa Maria Nuova
Reggio Emilia, Emilia-Romagna, 42100, Italy
-
Azienda Osp Uni Seconda Università Degli Studi Di Napoli
Naples, Campania, 80131, Italy
-
Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi
Palermo, Sicily, 90127, Italy
-
Azienda Ospedaliera Ordine Mauriziano di Torino
Turin, Piedmont, 10128, Italy
-
Azienda Ospedaliera San Camillo Forlanini
Rome, Lazio, 00151, Italy
-
Azlenda Ospendaliero-Universitaria Pisana
Pisa, Tuscany, 56100, Italy
-
Clinica Oncologica-Ospedali Riuniti Ancona
Torrette, Tuscany, 60020, Italy
-
Fondazione IRCCS Ospedale Maggiore Policlinico
Milan, Lombardy, 20122, Italy
-
Fondazione Pascale
Naples, Campania, 80100, Italy
-
IOV - Istituto Oncologico Veneto - IRCCS
Padova, Veneto, 35128, Italy
-
IRCCS Ospedale Casa Sollievo Della Sofferenza
San Giovanni Rotondo, Apulia, 71013, Italy
-
Istituto Clinico Humanitas
Rozzano, Lombardy, 20089, Italy
-
Istituto Nazionale Dei Tumori
Milan, Lombardy, 20133, Italy
-
Ospedale del Mare
Naples, Campania, 80147, Italy
-
Ospedali Riuniti - Bergamo
Bergamo, Lombardy, 24128, Italy
-
Policlinico Universitario Agostino Gemelli
Rome, Lazio, 00168, Italy